03/2021: Russian developer Mabscale in-licensed UGA Biopharma´s biosimilar cell lines
out-licensed two of its innovative ready-to-use biosimilar cell lines to
Russia-based biosimilar developer Mabscale, who will now conduct GMP
manufacturing and clinical studies to obtain marketing authorizations for the
lines in-licensed by Mabscale are among a wide range of ready-to-use biosimilar
cell lines for GMP manufacturing developed by UGA. These in-house developed
CHO-based cell lines stably express different biosimilar molecules to make them
instantly available for in-licensing. Client advantages include direct access
to proven cell lines that come bundled with all development data, including
high titer and assured quality attributes.
information, please click here.